Reported by CNBC-TV18 Markets, not nibnow. We are not the publisher of this story, only the source is.
Mankind Pharma’s operating margin widened to 27% from 24.9% a year earlier. Its board also approved plans to merge two wholly owned subsidiaries into the company.